The application value of combined testing of tumor markers and stool in the diagnosis and treatment of colorectal cancer
肿瘤标志物及粪便联合检验在结、直肠癌诊治中的应用价值

摘要

目的 探究结、直肠癌诊治中采取肿瘤标志物及粪便联合检验的价值。方法 本次研究对象为50例结、直肠癌患者，抽取时间为2023年1月-2024年1月。将上述患者设为实验组，另选同期入院进行健康体检的50例健康人员设为参考组。对上述两组均进行肿瘤标志物及粪便联合检验，观察对比两组检验结果，并分析肿瘤标志物及粪便联合检验的准确性、特异性及敏感性。结果 相较于参考组，实验组血便、黏液便以及痢疾样脓血便检出率较高（P＜0.05）。实验组血清中CEA、CA199较参考组高（P＜0.05）。粪便检验联合肿瘤标志物检测的准确性、特异性及敏感性均高于单一检验（P＜0.05）。结论 粪便检验与肿瘤标志物检测在结直肠癌的诊断中具有一定的参考价值。当粪便检验与肿瘤标志物检测联合应用时，能够显著提升诊断的准确性，并表现出较高的特异性和敏感性。

Abstract

Objective To explore the value of using tumor markers and stool combined testing in the diagnosis and treatment of colorectal cancer.
Methods The subjects of this study were 50 patients with colorectal cancer, selected from January 2023 to January 2024. Set the above patients as the experimental group, and select 50 healthy individuals who were admitted for health check ups during the same period as the reference group. Perform a combined test of tumor markers and stool for both groups mentioned above, observe and compare the test results of the two groups, and analyze the accuracy, specificity, and sensitivity of the combined test of tumor markers and stool.
Results Compared with the reference group, the experimental group had a higher detection rate of bloody stool, mucous stool, and dysentery like purulent stool (P<0.05). The levels of CEA and CA199 in the serum of the experimental group were higher than those in the reference group (P<0.05). The accuracy, specificity, and sensitivity of fecal examination combined with tumor marker detection were higher than those of single test (P<0.05).
Conclusion   Fecal examination and tumor marker detection have certain reference value in the diagnosis of colorectal cancer. When fecal testing is combined with tumor marker detection, it can significantly improve the accuracy of diagnosis and exhibit high specificity and sensitivity.